JBIO.US Jade Biosciences, Inc.

Healthcare Biotechnology USA Stocks
16.14 USD
Close of Nov 15, 2026
11.02 28.00
Market cap
USD 1.03B
P/E
-
P/B
2.33x
ROE
-43.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is JBIO.US undervalued?

Graham number

The Graham number of Jade Biosciences, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Jade Biosciences, Inc. fundamental analysis

No fundamental analysis for Jade Biosciences, Inc. yet.

Jade Biosciences, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Jade Biosciences, Inc.

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, In…

Full company profile